Sonnet BioTherapeutics, an oncology-focused biotech, presents its FHAB technology at EF Hutton Annual Global Conference on May 15, 2024.

Sonnet BioTherapeutics, an oncology-focused biotech firm, will present at the EF Hutton Annual Global Conference on May 15, 2024, in New York. Their proprietary FHAB technology uses human single-chain antibody fragments to target tumor and lymphatic tissues, improving drug safety and efficacy. EF Hutton LLC, the event's host, offers strategic advisory and financing solutions to clients worldwide.